Key Highlights

● Evogene said its ChemPass AI drug- and crop-chemical-design engine reached a new milestone with Google Cloud, embedding autonomous AI agents built on Gemini into its molecule-discovery workflow. The advance comes as the Israeli computational-biology company reports just $13.1 million in cash and shrinking revenue.

● As of March 31, 2026, Evogene reported consolidated cash, equivalents and short-term bank deposits of $13.1 million, with quarterly cash usage of about $2.8 million.

● Revenue is small and declining, cash is limited relative to quarterly burn, and the company has already relied on warrant-inducement financing this year, a pattern risking further dilution.

● Investors should watch for second-quarter 2026 results and cash position, due around the scheduled August 18, 2026 earnings call.

Evogene Ltd. (Nasdaq, TASE: EVGN), a Rehovot, Israel-based computational biology company, said on June 24, 2026 that it had reached "a major milestone" in its multi-year collaboration with Google Cloud, integrating autonomous AI agents built on Google's Gemini models into its ChemPass AI™ small-molecule discovery platform. The announcement builds on a partnership dating to October 2024, which has produced a generative foundation model (June 2025) and an agent-integration phase (February 2026). It lands as Evogene works to prove out ChemPass AI across pharmaceutical and agricultural subsidiaries, while first-quarter 2026 results show cash of $13.1 million, a steep revenue drop, and a widened net loss, underscoring the gap between technological ambition and financial runway.

What happened

Evogene's June 24, 2026 release described the newest phase of its Google Cloud collaboration as embedding agentic AI, powered by Gemini models and Google's Gemini Enterprise Agent Platform, into ChemPass AI. The company said the system can now autonomously integrate structural, biological, chemical and clinical data to build early-stage Target Product Profiles, flagging whether a molecule is likely to meet development criteria before significant R&D spending is committed. Boaz Maoz, Google Cloud Israel's managing director, said the work shows Evogene is "positioned to innovate and significantly accelerate the discovery of new molecules." CEO Ofer Haviv said the capabilities "may position us to address complex proteins that currently represent a challenge in the development of new therapies." Neither company disclosed financial terms. The milestone followed a February 10, 2026 announcement expanding the partnership to deploy AI agents via Vertex AI, and a June 2025 release on completion of the underlying generative foundation model.

Why the development matters

For a small computational-biology company, a continuing, multi-phase collaboration with a hyperscale cloud provider is a credibility signal, having progressed through several milestones over nearly two years rather than one announcement. If the agentic layer works as described, it could shorten Evogene's design-make-test-analyze cycles and let it run more discovery programs in parallel, useful for a company with limited cash to fund proprietary programs alone. Neither party has disclosed revenue-sharing or milestone payments, and the announcements describe technical capability rather than a validated candidate. The practical payoff, a partnered or internal molecule reaching meaningful preclinical or field-trial data, has not yet been demonstrated publicly.

Company and product background

Evogene operates a group of subsidiaries built around a shared computational discovery platform it calls its Computational Predictive Biology system, with ChemPass AI as the generative-AI engine for small-molecule design used across human-health and agricultural applications. AgPlenus, its agrochemical subsidiary, expanded ChemPass AI's agricultural use with a July 15, 2026 model predicting antifungal potency from chemical structure ahead of synthesis. Biomica, the microbiome-therapeutics arm, completed a Phase 1 study on June 2, 2026 for BMC128, evaluated alongside checkpoint inhibitor nivolumab. Casterra, focused on castor-oil crops for biofuel and industrial uses, reported successful commercial field trials in Brazil in March 2026. Lavie Bio, formerly the agricultural-biologicals arm, is no longer core: during 2025 it sold most of its operations to ICL Group Ltd., with remaining activity reported as discontinued operations. Newer pharma collaborations include a July 22, 2026 agreement with ELEO Inc. on oral PCSK9-pathway inhibitors and a February 2026 licensing deal with Shanghai Lishan Biopharmaceuticals for BMC128. Management's stated focus is converting ChemPass AI's progress into partnered programs while holding costs near a roughly $3.2 million quarterly run-rate it calls sustainable.

Financial position

As of March 31, 2026, Evogene reported consolidated cash, equivalents and short-term bank deposits of $13.1 million, with quarterly cash usage of about $2.8 million. First-quarter 2026 revenue was $0.3 million, down sharply from $2.3 million a year earlier, attributed largely to lower Casterra seed sales. Net loss for the quarter was $5.9 million, versus $3.0 million a year earlier, linked to the revenue decline and financing-related expenses. For full-year 2025, revenue was roughly $3.9 million (down from $5.6 million in 2024) and net loss about $7.8 million, narrower than 2024's $18.1 million. In February 2026 the company raised approximately $3.4 million in gross proceeds through a warrant-inducement transaction; it also carries a warrants liability tied to Series A-1 and B-1 warrants, valued at about $1.7 million at quarter-end. Evogene's stock traded around $0.49–$0.51 on July 30, 2026, against a 52-week range of roughly $0.37 to $1.50, with market capitalization estimated in the mid-single-digit millions (figures vary modestly by source). Given cash usage near $2.8–3.0 million per quarter against $13.1 million on hand, an estimated runway, not company guidance, would extend well under two years absent further financing, warrant exercises, licensing income or asset sales, implying continued dilution risk.

Bull case

A near two-year, multi-phase relationship with Google Cloud lends outside technical validation to ChemPass AI, and the platform now spans pharma (Biomica's clinical-stage asset, new licensing deals) and agriculture (AgPlenus's predictive models, Casterra's field-validated crops) rather than a single bet. The Lavie Bio divestiture and a full-year 2025 loss less than half of 2024's suggest cost discipline toward a sustainable base.

Risk case

Revenue is small and declining, cash is limited relative to quarterly burn, and the company has already relied on warrant-inducement financing this year, a pattern risking further dilution. The Google Cloud collaboration has produced technical milestones but no disclosed commercial terms or validated product candidate; agentic AI claims remain unproven outside company statements. A depressed, sub-$1 share price and micro-cap valuation reflect the market's own skepticism about near-term value creation.

What investors should watch next

Investors should track: second-quarter 2026 results and cash position, due around the scheduled August 18, 2026 earnings call; any disclosed commercial terms or named candidates emerging from the Google Cloud collaboration; Biomica's next steps for BMC128 after Phase 1; AgPlenus's commercialization timeline for its antifungal-potency model; and further financing, including warrant exercises or raises affecting share count.

Conclusion

Evogene's expanding Google Cloud collaboration is a genuine, multi-year partnership with successive, verifiable milestones, sitting atop broadening pharma and agricultural applications following the Lavie Bio divestiture. Whether the technology translates into disclosed licensing revenue or validated products remains unproven, and shrinking revenue, limited cash and reliance on warrant financing pose real near-term pressure. This article offers no investment recommendation; readers should weigh the collaboration's promise against Evogene's constrained balance sheet.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.